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Abstract
Objective
To characterize all 4 mutations described for CD59 congenital deficiency.
Methods
The 4mutations, p.Cys64Tyr, p.Asp24Val, p.Asp24Valfs*, and p.Ala16Alafs*, were described in
13 individuals with CD59 malfunction. All 13 presented with recurrent Guillain-Barre´ syn-
drome or chronic inflammatory demyelinating polyneuropathy, recurrent strokes, and chronic
hemolysis. Here, we track the molecular consequences of the 4 mutations and their effects on
CD59 expression, localization, glycosylation, degradation, secretion, and function. Mutants
were cloned and inserted into plasmids to analyze their expression, localization, and
functionality.
Results
Immunolabeling of myc-tagged wild-type (WT) and mutant CD59 proteins revealed cell
surface expression of p.Cys64Tyr and p.Asp24Val detected with the myc antibody, but no
labeling by anti-CD59 antibodies. In contrast, frameshift mutants p.Asp24Valfs* and
p.Ala16Alafs* were detected only intracellularly and did not reach the cell surface. Western blot
analysis showed normal glycosylation but mutant-specific secretion patterns. All mutants sig-
nificantly increased MAC-dependent cell lysis compared with WT. In contrast to CD59
knockout mice previously used to characterize phenotypic effects of CD59 perturbation, all 4
hCD59 mutations generate CD59 proteins that are expressed and may function intracellularly
(4) or on the cell membrane (2). None of the 4 CD59 mutants are detected by known anti-
CD59 antibodies, including the 2 variants present on the cell membrane. None of the 4 inhibits
membrane attack complex (MAC) formation.
Conclusions
All 4 mutants generate nonfunctional CD59, 2 are expressed as cell surface proteins that may
function in non–MAC-related interactions and 2 are expressed only intracellularly. Distinct
secretion of soluble CD59 may have also a role in disease pathogenesis.
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Complement activation triggers membrane attack complex
(MAC) assembly to formpores in cell membrane lipid bilayers of
susceptible bacteria.1 However, unregulated MAC formation
may cause host tissue damage.2 The glycosyl phosphatidylinositol
(GPI)-anchored cell surface membrane glycoprotein CD59
inhibits the final step of MAC formation to protect host cells
from MAC-mediated injury.3
Several mutations in the CD59-coding sequence are known
in human patients (figure 1A). We and others have pre-
viously reported of 13 patients4–11 aged 1–4.5 years who
suffered from chronic hemolysis and recurrent episodes of
Guillain-Barre´ syndrome (GBS)-like disease from early
infancy, suggesting chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP), and recurrent strokes
(table e-1, links.lww.com/NXG/A87). The mutations in-
cluded p.Cys64Tyr, p.Asp24Val, p.Asp24Valfs*, and
p.Ala16Alafs*, all leading to CD59 loss of function. In all
mutations, no surface protein was detected by anti-CD59
antibody staining. We were interested, in the current study,
to verify whether indeed no proteins were produced,
whether any proteins that were produced reached the
membrane, and whether proteins or truncated proteins
exist intracellularly or secreted outside the cells. These
potential differences may have functional implications and
clinical manifestations.
Methods
Generation of myc-tagged wild-type (WT) and
mutant hCD59 expression plasmids
To verify the membrane and intracellular localization of the
mutated protein, we isolated, myc-tagged, and expressed WT
CD59 and each mutant in mammalian cell lines. Total RNA
was extracted from human white blood cell samples using
TRI Reagent (Sigma, St Louis, MO). cDNAs generated by
SuperScript II Reverse Transcriptase (Life Technologies,
Carlsbad, CA) from RNAs isolated from both a Cys64Tyr
homozygous patient and a healthy individual were used as
templates for PCR reactions (details appear in a supplemen-
tary section of Methods links.lww.com/NXG/A88).
Antibodies
To test staining of WT and mutant CD59 by anti-CD59
antibodies, human CD59 antibodies were used in im-
munofluorescence labeling assays of overexpressing
COS7 cells and detected by flow cytometry and fluo-
rescent microscopy. Details appear in supplementary
section.
Sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) and Western blotting and
immunoprecipitation
SDS-PAGE, Western blot, and immunoprecipitation were used
forCD59 detection (details appear in the supplementary section).
Bortezomib (proteasome inhibitor) treatment
To test the effect of ubiquitination on expression, we inhibited
ubiquitination by bortezomib. Forty-eight hours after trans-
fection, culture medium was supplemented with 10 nM bor-
tezomib (Velcade, Cell Signaling) or vehicle-only control. A
mouse antibody against the myc-tag peptide was used for
Western blot analysis.
In vitro cell lysis assay assessing MAC attack in WT and
mutants
To evaluate deposition of MAC and cell lysis, we used in vitro
cell lysis assays. Transfections of Chinese hamster ovary
(CHO) cells were performed using Lipofectamine 2000 re-
agent. Details appear in the supplementary section. Cells were
harvested 24 hours after transfection, replated on 24-well plates
(3 × 105 cells in 1 mL per well), and left until the plates were
confluent. Cells were then washed twice with serum-free me-
dium and incubated in 0.25 mL complete medium (7.5% FCS
heat inactivated) containing a 1/750 dilution of calcein AM
(Molecular Probes, Eugene, OR, 1 mg/mL stock in dimethyl
sulfoxide) for 1 hour at 37°C. After 1 wash with phosphate
buffered saline (PBS), duplicate wells were incubated with 1/5
dilution of normal human serum and 40 μL of rabbit anti-CHO
immunoglobulin G (IgG). After incubation for 1 hour at 37°C,
all fluid was removed from the cells and transferred to 96-well
plates for calcein measurement.
The remaining cells were lysed with 0.25 mL PBS containing
0.1% Triton X-100 during a 15-minute incubation period at
room temperature, and the lysate was removed to 96-well
plates for calcein release measurement. Calcein fluorescence
of supernatants was read in a Cytation 3 Cell Imaging Multi-
Mode Reader (BioTek, Winoosky, VT) with excitation and
emission filters set at 485 and 530 nm, respectively. Percent
lysis for each well was calculated as calcein release/total cal-
cein loading. Mean values and SDs were determined from
duplicate samples. Analysis of variance (ANOVA) and Stu-
dent t test were used for statistical analysis.
Structural biology
Pymol (Schro¨dinger LLC, New York, NY) was used for in-
spection of structures and figure generation. Models of the
frameshift peptide sequences were generated using the
I-TASSER server.12–14
Glossary
CIDP = chronic inflammatory demyelinating polyradiculoneuropathy; ER = endoplasmic reticulum; GBS = Guillain-Barre´
syndrome; MAC = membrane attack complex; PNH = paroxysmal nocturnal hemoglobinuria; SDS-PAGE = sodium dodecyl
sulfate–polyacrylamide gel electrophoresis; WT = wild type.
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Standard protocol approvals, registrations, and
patient consents
Human DNA and tissue samples were obtained in protocols
approved by our institutional review board. All patients or
their families provided informed consent.
Data availability
Study data for the primary analyses presented in this report
are available upon reasonable request from the corresponding
and senior author.
Results
Predicted effect of CD59 mutations on its 3D
protein structure
Figure 1 shows the sequences (figure 1A) and structures (figure
1, B and C) of CD59 with residues mutated in the 2 described
point mutations (figure 1B). The similarities between the 2
frameshift mutants are highlighted (figure 1C). The mature
membrane surface–expressed CD59 sequence consists of 77
residues after removal of a 25-residue N-terminal signal se-
quence and a C-terminal GPI-anchoring signal.15
Inspection of solved structures of CD59,16 pdb IDs 2j8b,
2uwr, 2ux2,17 4bik,18 and 2ofs19 shows that in the p.Cys64Tyr
mutant, a local disulfide bridge near the carboxy terminus of
the mature protein is interrupted (Cys64-Cys69) (figure 1B).
This would probably merely loosen the loop that is followed
by the C-terminal helix, which adopts different orientations
depending on the solved structure (e.g., 2j8b vs 2uwr), in-
dicating that it is not strongly stabilized in the WT structure.
As for p.Asp24Val, Asp24 was previously reported to play an
important role in CD59 stability and activity: p.Asp24Ala
strongly destabilizes CD59,20 whereas p.Asp24Arg permits
protein folding and expression, but abolishes CD59 activity.21
Indeed, Asp24 is part of an exposed loop (Ser20-Asp24),
located between the second and third β-strands (figure 1B),
that is involved in modulating CD59 activity. Single mutations
to alanine in that loop increased, whereas multiple alanine
Figure 1 Sequence and structure of CD59 WT and mutants
(A) The sequences of WT CD59, point
mutations Cys64Tyr and Asp24Val, and
frameshift mutations Asp24Valfs* and
Ala16Alafs*: The mature membrane
surface CD59 primary sequence con-
sists of 77 residues after removal of
a 25-residue N-terminal signal se-
quence and a C-terminal GPI-anchor-
ing signal (not shown). Colored arrows
and boxes represent β-strands and
α-helices, respectively, as observed in
WT CD59 (see B). Point mutations are
marked with an asterisk. The sequence
of the 2 frameshift mutants reveals
significantly shortened proteins that
lack most of the CD59 sequence, in
particular the GPI-anchoring signal. (B)
The structure of CD59 highlights the
vicinity of the point mutations to
known sites of activity and interaction.
The mutated Cys64 and Asp24 posi-
tions are highlighted as spheres and
labeled. The 3 characterized interfaces
of CD59 are marked by numbered
crescents: (1) The classic site charac-
terized originally described by Bodian
et al.21 with the central Trp40 residue
shown in sticks, (2) a loop spanning
residues 20–24 that modulates CD59
activity20 (colored in white), and (3) the
edge β-strand that interacts with ILY18
(to the left of the crescent). Disulfide
bridges that stabilize CD59 are shown
in sticks. Two solved structures (2j8b
and 2uwr) are shown, highlighting the
relative flexibility of the C-terminal he-
lix (colored in magenta). (C) The
frameshift mutants contain only
a small part of the original CD59 se-
quence: The structure of CD59 is
shown, with the regionwith a sequence
in common with the Ala16Alafs* and
Asp24Valfs* mutants colored in yellow
and yellow-white, respectively. The I-
TASSER model for the Asp24Valfs* se-
quence aligns 2 additional β-strands
(colored in green, ending with the
sphere at CD59 position Trp40), before
it diverges, and the remaining part (in
blue) is unique to CD59. GPI = glyco-
syl phosphatidylinositol; WT = wild type.
Neurology.org/NG Neurology: Genetics | Volume 4, Number 6 | December 2018 3
substitutions decreased its activity.20 The 2 other mutants,
p.Ala16Alafs and p.Asp24Valfs, contain frameshifts that lead
to premature termination of the protein chain (figure 1A).
The frameshift mutants result in two 53 residue proteins
with very different structure compared with WT CD59, but
their sequences are similar (figure 1A), including a common
C-terminus that lacks the GPI anchor attachment signal and
thus cannot attach to the membrane. Consequently, neither is
expected to successfully proceed via the Golgi apparatus to
the cell surface. The resulting proteins most probably do not
fold into a stable structure, in particular the Ala16Alafs* mu-
tation (figure 1C), as estimated by the low quality of the
models predicted by the I-TASSER server12–14 (see
Methods).
Western blot analysis of CD59 mutants
To characterize the expression of CD59 mutants, we per-
formed Western blot analysis. We myc-tagged WT and all 4
CD59mutants, p.Cys64Tyr, p.Asp24Val, p.Asp24Valfs*, and
p.Ala16Alafs*, as well as GFP as a control, and expressed
each in HEK293T cells. Lysates were separated in SDS-
PAGE gels and immunoblotted with the anti-myc antibody.
Western blot analysis of whole-cell lysate probed with the
anti-myc antibody revealed similar patterns of the myc
antibody for WT CD59 myc protein and the missense mu-
tant p.Cys64Tyr myc protein. In both, 2 bands were seen, 1
between 20 and 25 kDa and the other between 15 and 20
kDa (figure 2A). The missense mutant p.Asp24Val myc
protein appeared as bands between 15 and 20 kDa. For
frameshift mutations p.Asp24Valfs* and p.Ala16Alafs*, very
weak bands between 10 and 15 kDa were identified (figure
2A). To test whether the 2 bands seen in WT and
p.Cys64Tyr proteins result from N-glycosylation in the
Golgi apparatus, cell lysates were treated with Endo H. The
data showed that the 20-kDa band represents glycosylated
protein, and the Cys64Tyr mutant is glycosylated to the
same extent as the WT protein (figure 2B).
p.Cys64Tyr reduces the ability of CD59 to be
secreted from the cell
Different processes, including cell damage and activation,
induce the release of membrane-anchored proteins from the
cell surface (shedding) or secretion from within the cell.
CD59 can be released into the circulation or the interstitial
fluid in a soluble form (sCD59) and can be detected in various
body fluids including urine, milk, serum, and plasma.22–25
Various studies have designated sCD59 as biomarker for
disease activity. Elevated circulating sCD59 concentrations
Figure 2Western blot profile
See Methods for details. Anti-myc was used in all assays for detection. (A) Western blot expression pattern of WT and mutants Cys64Tyr, Asp24Val,
Asp24Valfs*, and Ala16Alafs*, as well as GFP. Anti-myc was used for detection (upper panel) and anti-tubulin as a loading control (lower panel). (B) Western
blot expression pattern ofWT and Cys64Tyrmutant and GFP after using the Endo H enzyme. (C) Western blot expression pattern of conditionedmedium. (D)
Proteosomal degradation profile. Transfected cells treated with bortezomib (Velcade) and lysate sample were separated on 15% polyacrylamide gels. PVDF
membranes were used for protein transfer. Anti-tubulin was used as a loading control (lower panel). PVDF = polyvinylidene difluoride; WT = wild type.
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have been found in acute myocardial infarction, and higher
serum titers of glycated sCD59 have been described in di-
abetes mellitus.26 To examine whether CD59 is secreted, we
checked the conditioned media of HEK293T cells trans-
fected with all the above myc constructs for the presence of
CD59. Conditioned media from WT, p.Cys64Tyr,
p.Asp24Val, p.Asp24Valfs*, and p.Ala16Alafs* CD59, as well
as GFP-transfected cells, were collected and subjected to
immunoprecipitation using anti-myc antibodies. Western
blot analysis of the precipitated proteins showed a single
band between 15 and 20 kDa (equivalent to the glycosylated
protein) for WT and p.Cys64Tyr and a single band of
slightly lower MW for p.Asp24Val; p.Asp24Valfs* superna-
tant showed a single major band at ;15 kDa, whereas no
secreted protein was detected for p.Ala16Alafs*. Of note,
much lower levels of secreted protein were detected for
p.Cys64Tyr CD59 myc compared with WTCD59-myc
(figure 2C). Both frameshift mutants have a signal peptide
but lack the GPI anchor attachment signal and are therefore
expected to be secreted from the cell. Of interest, whereas
p.Asp24Valfs* was indeed secreted, no secretion was seen for
p.Ala16Alafs* (figure 2C).
Proteosomal degradation profile
We further examined whether the CD59 mutants
p.Cys64Tyr, p.Asp24Val, p.Asp24Valfs*, and p.Ala16Alafs*
are abnormally degraded via the ubiquitin-proteasome
pathway. For this, we treated the lysate of HEK293T
cells transfected with the above myc-tagged mutants
with bortezomib, a proteasome inhibitor. Cell lysates were
separated by SDS-PAGE and immunoblotted with an anti-
myc antibody (figure 2D). This experiment revealed that
the p.Cys64Tyr myc and p.Asp24Val myc mutants, similar
to the WT protein, do not accumulate in cells on inhibition
of the proteasome. In contrast, the frameshift mutants,
p.Asp24Valfs* myc and p.Ala16Alafs* myc, do accumulate,
indicating that they are subject to proteasome degradation
(figure 2D).
Intracellular and membrane localization of
CD59 mutants
To examine CD59 localization, we expressed in COS7 cells
myc-taggedWTCD59 and the 4 mutants of interest, as well as
GFP as a negative control, and detected surface-expressed
proteins by staining with the specific anti-myc antibody. In cells
Figure 3 Surface and intracellular localization of hCD59 mutants
(A) Characterization ofWT andmutant Cys64Tyr, Asp24Val, Asp24Valfs*, and Ala16Alafs* constructs bymyc antibody (red) and DAPI (blue). Staining withmyc
tag and secondary antibodies was added after fixationwithout Triton. (B) Characterization ofWT and Asp24Valfs* and Ala16Alafs* CD59mutants by anti-myc
antibodies with or without Triton permeabilization. Differential recognition of WT and the Asp24Valfs* and Ala16Alafs* CD59 mutants by anti-myc. In both
procedures, anti-myc detected the WT constructs with or without Triton, but in the mutant construct, ER staining was seen only with Triton. (C) Character-
ization of WT and Asp24Valfs* and Ala16Alafs* CD59 mutants by anti-myc and PDI antibodies. Upper panel: myc antibody (red); middle panel: PDI antibody
(green) andDAPI (blue); and lower panel:merge. Cells were treatedwithmethanol for permeabilization. Scale bars = 50μm. PDI = protein disulfide isomerase;
WT = wild type.
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expressing WT, p.Cys64Tyr, and p.Asp24Val constructs, cell
surface localization was detected by themyc antibody, whereras
no surface staining was seen in cells expressing p.Asp24Valfs*
and p.Ala16Alafs* constructs (figure 3A). Because we could not
detect any surface staining in the 2-frameshift mutants, we re-
peated the immunolabeling procedures on fixed cells, with or
without membrane permeabilization by Triton-X100. When
immunolabeling procedures were performed without Triton,
themyc antibody clearly detectedWTCD59on the cell surface,
but not the frameshift mutants p.Asp24Valfs* and p.Ala16Alafs*
(figure 3B upper panel). After Triton permeabilization, how-
ever, the myc antibody stained the 2 frameshift mutant CD59
proteins intracellularly, presumably in the endoplasmic re-
ticulum (ER) (figure 3B lower panel). To verify the ER staining
of the frameshift mutations, we double labeled the transfected
COS7 cells with anti-myc and an anti-PDI antibody, an ER
marker. Immunolabeling revealed clear colocalization demon-
strating that both frameshift mutants localized to the ER (figure
3C). To summarize, although both missense mutants
p.Cys64Tyr and p.Asp24Val are expressed on the cell surface,
the frameshift mutants p.Asp24Valfs* and p.Ala16Alafs* fail to
reach the cell surface and remain in the ER.
These results are in agreement with Western blot expression
results (figure 2, C and D), indicating that the missense
mutants are expressed and stable at the cell surface, whereas
the frameshift mutants are retained in the ER, fromwhich they
are secreted from the cell (in the case of p.Asp24Valfs*) or
sent to proteosomal degradation (both p.Asp24Valfs* and
p.Ala16Alafs*).
CD59 mutants are not detected by anti-
CD59 antibodies
To investigate whether any of the available anti-CD59
antibodies detect the surface-expressed mutants, patient-
derived Cys64Tyr-expressing and healthy control lympho-
blasts were exposed to 5 different hCD59 monoclonal
antibodies representing mapped epitopes MEM43, HC1,
BRIC229, YTH53.1, and A35,21 1 monoclonal antibody with
an unknown epitope, 1.39, and a rabbit polyclonal antiserum
raised against human CD59. By flow cytometry, detection of
CD59 by each of these 7 antibodies occurred only in the
control lymphoblasts and not in lymphoblasts expressing
CD59 mutants (figure 4A). We further verified these results
using cells transfected with WT mutant, both missense
mutants p.Cys64Tyr and p.Asp24Val and the 2 frameshift
mutants p.Asp24Valfs* and p.Ala16Alafs* by immunofluo-
rescence. Transfected cells were immunolabeled with each
of the above human CD59 antibodies and, in parallel, with
the anti-myc antibody. Immunolabeling with the mono-
clonal antibodies, MEM43, BRIC229 (figure 4B), HC1, 1.39
(figure e-2) and rabbit polyclonal antibodies (data not
shown) revealed clear cell surface detection of the WT but
not the mutant constructs (figure 4B). For technical reasons,
A35 and YTH53.1 were not included in the staining. Results
of the immunofluorescence labeling, including the myc an-
tibody, are summarized in table e-2 (links.lww.com/NXG/
A87). Taken together, known anti-CD59 antibodies did not
detect surface expression of CD59 protein in either of the 2
missense mutations. This may suggest that the missense
mutations result in substantial structural changes that abol-
ish the protein’s interaction with various antibodies and may
similarly abolish protein-protein interactions necessary for
its different functions.
CD59 p.Cys64Tyr and p.Asp24Val mutants are
nonfunctional in protecting from MAC attack
All 7 patients described with the p.Cys64Tyr mutation, and all
3 patients described with the Asp24Val mutation exhibited
paroxysmal nocturnal hemoglobinuria (PNH)-like RBC he-
molysis and a hypercoagulability state6,9 due to increased
MAC formation. We expressed WT and mutant hCD59
constructs in the CHO cells and examined MAC-dependent
lysis of the transfected cells. As shown in figure 5, WT CD59
transfection protected CHO cells from lysis (p < 0.05,
ANOVA and Student t test); however, all mutants, including
p.Cys64Tyr and p.Asp24Val, showed significantly increased
MAC-dependent cell lysis (p < 0.05, ANOVA and Student t
test for frameshift mutants and p.Asp24Val) compared with
the level of MAC-dependent cell lysis in the presence of WT
hCD59. For the p.Cys64Tyr mutant, this measured lysis (p <
0.002, ANOVA and Student t test) even surpassed the lysis of
CHO cells without any additional expression, indicating
perhaps an agonist effect on MAC-dependent lysis that needs
further investigation.
Taken together, we conclude that although both p.Cys64Tyr
and p.Asp24Val mutant CD59 are surface expressed as
demonstrated by myc staining, they are not detected by any of
a panel of anti-CD59 antibodies using flow cytometry or
immunofluorescence labeling and do not protect against
MAC killing. The data indicate that these mutant proteins are
misfolded and, similar to the frameshift mutations, show no
CD59 function in relation to protection against MAC.
Discussion
SecondaryCD59 deficiency is a common finding in patients with
PNH. This condition is characterized by clonal expansion of
hematopoietic stem cells that have acquired a somatic mutation
in the PIGA gene (phosphatidylinositol N-acetylglucosaminyl-
transferase subunit A). PIGA encodes a GPI biosynthesis
protein, phosphatidylinositol N-acetylglucosaminyltransferase
subunit A.27,28 The CD59 protein inhibits the final and most
important step of MAC formation. Erythrocytes that are de-
ficient in GPI-anchored membrane proteins, including CD59,
undergo complement-mediated hemolysis.29,30
The relationship of CD59 deficiency to the erythrocyte
phenotypes of PNH has been established.31–34 Indeed, in
a murine model, targeted deletion of the CD59 gene resulted
in spontaneous intravascular hemolysis and hemoglobinuria,
findings characteristic of PNH.35
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Figure 4Mutant detection by anti-CD59 antibodies using flow cytometry and fluorescent microscopy
(A) A panel of anti-CD59 antibodies in Cys64Tyr andhealthy control lymphoblasts:MEM43, HC1, BRIC229, YTH53.1, A35, 1.39, and rabbit polyclonal antibodies,
assayed by flow cytometry. (B) Staining of WT and mutant constructs Cys64Tyr, Asp24Val, Asp24Valfs*, and Ala16Alafs* by BRIC229 or MEM43f (red), DAPI
(blue). Procedures were performed by live staining without fixation and Triton treatment and assayed by fluorescent microscopy. Scale bars = 50 μm.
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PNH is a rare disease, affecting approximately 1 per million in
Caucasian populations. Primary CD59 deficiency caused by
germline mutations is extremely rare, described so far in 13
individuals globally, and characterized by hemolytic anemia
(13/13), recurrent strokes (7/13), and peripheral de-
myelination (12/13) imitating recurrent GBS or CIDP.6,29,30
The 4 CD59 mutations described so far have similar clinical
manifestations, despite large differences between the mutant
proteins. The frameshift mutants p.Asp24Valfs* and
p.Ala16Alafs* are predicted to generate truncated proteins
with a distinct C-terminal sequence (common to both
mutants) and as we show here undergo either ubiquitination
or secretion and do not reach the membrane surface. In
contrast, the mutants p.Cys64Tyr and p.Asp24Val do reach
the cell surface but are nonfunctional in protecting the host
from MAC attack; nevertheless, these proteins have the po-
tential capability to perform non–MAC-related functions.
The MAC inhibitory function of CD59 is related to its ca-
pacity to bind C8 (within C5b-8) and block recruitment of
C9, essential for MAC formation, accounting for the observed
effect on lytic sensitivity.36,37 The region in CD59 responsible
for interaction with these complement proteins has been
defined by analysis of engineered CD59mutants, and includes
positions Trp40, Arg53, and Glu56, which colocalize to the
glycosylated, membrane-distal face of its extracellular domain,
and a distal position Asp24.21 Of note, the latter is the position
mutated in the p.Asp24Val point mutation. In another study,
this residue was shown to be part of a loop spanning residues
20–24 that effectively modulates CD59 activity; engineered
mutations in this loop both reduced and increased CD59
activity, highlighting its role in fine-tuning CD59 function.20
A recently solved structure of a complex between the patho-
gen pore-forming intermedilysin (ILY) and CD59 (PDB ID
4bki)18 revealed another distinct binding site on CD59 that
promotes polymerization of ILY on the cell surface and cat-
alyzes pore formation.18 Cys64 is located in this third interface
(figure 1B), suggesting that, in addition to a destabilizing ef-
fect leading to loss of recognition by antibodies and loss of
MAC regulatory function, the Cys64Tyr mutation could also
specifically affect other interactions. The fact that hCD59
Cys64Tyr overexpression caused increased MAC-dependent
lysis beyond the control, in marked contrast to the lytic in-
hibitory effect of WT, may indicate an involvement of this
interface in the regulation of MAC formation. The interface
may also mediate functional interactions with complement or
other players, such as activation of T cells38,39 and Islet cell
secretion of insulin.40
The mutations reported in this study, together with previous
studies on CD59 activity, highlight the versatility of CD59
activity and regulation. CD59 likely acts via at least 3 distinct
interfaces (figure 1B): (1) The binding site was originally de-
fined21 between the β-sheet and α-helices 1&2; (2) loop 20–24,
which fine tunes activity20; and (3) the β-strand interface
binding to the pathogen intermedilysin.18 The latter 2 are di-
rectly affected by the CD59 point mutations described in this
study. In humans, and in contrast to CD59 knockout experi-
ments in mice, the present study shows a much more complex
picture of mutated CD59 expression and mode of action.
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Figure 5 Lysis functional assay in hCD59 mutants
WT and mutant constructs Cys64Tyr, Asp24Val,
Asp24Valfs*, and Ala16Alafs* were transfected to
CHO cells. Forty-eight hours after transfection,
cells were marked by calcein AM, and calcein
fluorescence of supernatants was read using the
Cytation 3 Cell Imaging Multi-Mode Reader with
the excitation filter set at 485 nm and emission
filter at 530 nm. Percent lysis for each well was
calculated as calcein release/total calcein loading
(*p < 0.05, **p < 0.002, ANOVA and Student t test).
WT = wild type.
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